CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Impact of intravascular ultrasound-guided percutaneous coronary intervention on long-term clinical outcomes in a real world population First-in-man evaluation of intravascular optical frequency domain imaging (OFDI) of Terumo: a comparison with intravascular ultrasound and quantitative coronary angiography Consensus from the 5th European Bifurcation Club meeting Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study A Randomized Study of Distal Filter Protection Versus Conventional Treatment During Percutaneous Coronary Intervention in Patients With Attenuated Plaque Identified by Intravascular Ultrasound SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed Nuclear Imaging of the Cardiac Sympathetic Nervous System: A Disease-Specific Interpretation in Heart Failure The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study
|<<... 74 75 76 77 78 79 80 ...>>|

Clinical Trial2019 May 14;40(19):1553-1562.

JOURNAL：Eur Heart J. Article Link

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

Oldgren J, Steg PG, Hohnloser SH et al. Keywords: atrial fibrillation with PCI history; dabigatran with P2Y12 inhibitor vs warfarin with P2Y12 inhibitor and aspirin; major bleeding

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top